MEN1 and acute myeloid leukemia: For DOT1L, combine pinometostat or next-generation inhibitors with menin inhibitors or HMA/venetoclax in KMT2A-rearranged AML, guided by H3K79me and MRD readouts (Chatzilygeroudi et al., 2025).